Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma

SIMPLE SUMMARY: Adoptive cell transfer (ACT) is a potentially robust treatment option for patients with advanced melanoma that is resistant to immune checkpoint inhibitors. The addition of cyclin-dependent kinase 4/6 inhibitors to combination BRAF-MEK inhibitors can also greatly improve the duration...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, Peter Kar Han, Cullinane, Carleen, Jackson, Susan, Walker, Rachael, Smith, Lorey K., Slater, Alison, Kirby, Laura, Patel, Riyaben P., von Scheidt, Bianca, Slaney, Clare Y., McArthur, Grant A., Sheppard, Karen E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699814/
https://www.ncbi.nlm.nih.gov/pubmed/34944961
http://dx.doi.org/10.3390/cancers13246342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699814/
https://www.ncbi.nlm.nih.gov/pubmed/34944961
http://dx.doi.org/10.3390/cancers13246342

Ejemplares similares